These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 9154316)
41. Megakaryocytes and platelets in vascular disease. van der Loo B; Martin JF Baillieres Clin Haematol; 1997 Feb; 10(1):109-23. PubMed ID: 9154318 [TBL] [Abstract][Full Text] [Related]
42. Analysis of megakaryocyte ploidy in patients with thrombocytosis. Kanz L; Hollen C; Friese P; Burstein SA Int J Cell Cloning; 1990 Jul; 8(4):299-306. PubMed ID: 2401806 [TBL] [Abstract][Full Text] [Related]
43. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification. Thiele J; Kvasnicka HM; Fischer R Ann Hematol; 1999 Nov; 78(11):495-506. PubMed ID: 10602893 [TBL] [Abstract][Full Text] [Related]
44. Proliferation in liquid culture of megakaryocytes from the blood of patients with primary myelofibrosis and other myeloproliferative disorders. Hibbin JA; Matutes E; Goldman JM Leuk Res; 1985; 9(9):1171-9. PubMed ID: 4068750 [TBL] [Abstract][Full Text] [Related]
45. Aberrant proplatelet formation in chronic myeloproliferative neoplasms. Muth M; Büsche G; Bock O; Hussein K; Kreipe H Leuk Res; 2010 Nov; 34(11):1424-9. PubMed ID: 20430444 [TBL] [Abstract][Full Text] [Related]
46. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis. Evrard S; Bluteau O; Tulliez M; Rameau P; Gonin P; Zetterberg E; Palmblad J; Bonnefoy A; Villeval JL; Vainchenker W; Giraudier S; Wagner-Ballon O Blood; 2011 Jan; 117(1):246-9. PubMed ID: 20944070 [TBL] [Abstract][Full Text] [Related]
47. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders. Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836 [TBL] [Abstract][Full Text] [Related]
48. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [TBL] [Abstract][Full Text] [Related]
49. The colony forming cell in the myeloproliferative disorders and aplastic anaemia. Rickard KA; Brown RD; Wilkinson T; Kronenberg H Scand J Haematol; 1979 Feb; 22(2):121-8. PubMed ID: 285455 [TBL] [Abstract][Full Text] [Related]
50. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Le Bousse-Kerdilès MC; Martyré MC Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553 [TBL] [Abstract][Full Text] [Related]
51. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861 [TBL] [Abstract][Full Text] [Related]
52. Spontaneous proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: is thrombopoietin the link? Bellucci S; Michiels JJ Ann Hematol; 2000 Feb; 79(2):51-8. PubMed ID: 10741915 [TBL] [Abstract][Full Text] [Related]
55. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms. Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717 [TBL] [Abstract][Full Text] [Related]
56. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Hibbin JA; Njoku OS; Matutes E; Lewis SM; Goldman JM Br J Haematol; 1984 Jul; 57(3):495-503. PubMed ID: 6743569 [TBL] [Abstract][Full Text] [Related]
57. Histomorphometric study of megakaryocytes in bone marrow in selected myeloproliferative and lymphoproliferative diseases. Lemancewicz D; Dziecioł J; Kłoczko J; Litwiejko-Pietryńczak E; Bogusłowicz W Folia Morphol (Warsz); 2003 Feb; 62(1):51-6. PubMed ID: 12769178 [TBL] [Abstract][Full Text] [Related]
58. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome]. Brière J Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652 [TBL] [Abstract][Full Text] [Related]
59. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Bellucci S; Michiels JJ Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614 [TBL] [Abstract][Full Text] [Related]
60. Abnormal clones of megakaryocytes in myeloproliferative disorders. Sato Y; Suda T Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1705-18. PubMed ID: 3471029 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]